The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

Asthika Goonewardene, an analyst from Truist Financial, has initiated a new Buy rating on BioNTech SE (BNTX).Stay Ahead of the Market:Discover ...

Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it ...

The BioNTech SE ADR BNTX slipped 3.73% to $122.15 Wednesday, on what proved to be an all-around favorable trading session for ...

The BioNTech SE ADR BNTX rose 5.55% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...

The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...

Moderna stock surged Tuesday after the Centers for Disease Control and Prevention noted a two-week spike in positive Covid tests.

Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.

The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.

Shares of BioNTech slipped 0.83% in after-hours trading on Friday after the company said it would pay $791.5 million in a ...

Also, Penn settled a lawsuit with the German drug manufacturer BioNTech, which, with Pfizer, made the COVID vaccine using ...

Key Insights Significant control over BioNTech by private equity firms implies that the general public has more ...